Corvus Pharmaceuticals Q1 2020 Earnings Report
Key Takeaways
Corvus Pharmaceuticals reported a net loss of $12.9 million for the first quarter ended March 31, 2020, and had cash, cash equivalents and marketable securities totaling $68.7 million at March 31, 2020.
Continued enrolling patients across three clinical stage programs.
Reported positive data updates for ciforadenant, the Adenosine Gene Signature, and CPI-818.
Adapted and updated study protocols to ensure patient and healthcare provider safety in light of the COVID-19 pandemic.
Revised financial forecast for 2020, expecting net cash used in operating activities to be between $29 million and $31 million.
Corvus Pharmaceuticals
Corvus Pharmaceuticals
Forward Guidance
Corvus has revised its financial forecast for 2020 and now expects full year 2020 net cash used in operating activities to be between $29 million and $31 million.